---
document_datetime: 2025-10-21 13:55:58
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/besremi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: besremi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.3214697
conversion_datetime: 2025-12-22 17:19:04.990449
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Besremi

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I.11 Introduction of, or change(s) to, the | 21/10/2025                          | N/A                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000295474                     | obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Change in due date for category 1, 2 or 3 studies in the RMP and/or Annex II - Accepted C.I.11.z - to update the RMP to revise the Post-Authorisation Safety Study (PASS, category 3) milestone dates. The proposal date for the Final report has changed from 'Q4 2025' to 'Q1 2026.'                                                                            |            |     |      |                 |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|-----------------|
| Variation type II / EMA/VR/0000277854 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.8 of the SmPC in order to correct Table 1 in Section 4.8 Undesirable effects due to an error in the statistical report. In addition, the MAH took the opportunity to introduce editorial changes to the PI, and DE, DK, NL PIs. | 04/09/2025 |     | SmPC | Not applicable. |
| Variation type II / EMA/VR/0000269531 | This was an application for a group of variations. B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished                                                                                                                                                                                                                                                                                                 | 04/09/2025 | N/A |      |                 |

<div style=\"page-break-after: always\"></div>

|                                       | product - B.II.b.1.c Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for biological/ immunological medicinal products, or for pharmaceutical forms manufactured by complex manufacturing processes - Accepted B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.a Tightening of specification limits - Accepted   |            |     |    |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----|
| Variation type IB / EMA/VR/0000246850 | This was an application for a group of variations. B.IV.1.a Addition or replacement of a device which is not an integrated part of the primary packaging - B.IV.1.a.1 Device with CE marking - Accepted                                                                                                                                                                                                                              | 29/03/2025 |     | PL |
| Variation type IA / EMA/VR/0000261647 | B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted                                                                                                                                                                                                                                                       | 25/03/2025 | N/A |    |
| Variation type IB / EMA/VR/0000258987 | B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                           | 25/03/2025 | N/A |    |

<div style=\"page-break-after: always\"></div>

| of the active substance - Accepted   |
|--------------------------------------|